argenx upgraded by Robert W. Baird with a new price target
$ARGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2025 | $918.00 | Buy | Truist |
| 9/11/2025 | Buy → Hold | Deutsche Bank | |
| 8/25/2025 | $850.00 | Outperform | RBC Capital Mkts |
| 7/8/2025 | Hold → Buy | Deutsche Bank | |
| 7/3/2025 | $700.00 | Overweight | Morgan Stanley |
| 5/13/2025 | $680.00 | Neutral → Outperform | Robert W. Baird |
| 3/17/2025 | Mkt Perform → Outperform | Bernstein | |
| 3/12/2025 | Sell → Hold | Deutsche Bank |
Truist resumed coverage of argenx with a rating of Buy and set a new price target of $918.00
Deutsche Bank downgraded argenx from Buy to Hold
RBC Capital Mkts initiated coverage of argenx with a rating of Outperform and set a new price target of $850.00
In the news release, argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada, issued 05-Nov-2025 by argenx Canada Inc. over CNW, we are advised by the company that the quote in the third paragraph has been revised. The complete, corrected release follows: argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada VYVGART® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, ta
VYVGART® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted therapy for CIDP treatment in 30 years TORONTO, Nov. 5, 2025 /CNW/ - argenx SE (EURONEXT: ARGX) (NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC (efgartigimod alfa injection) as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP).
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. "argenx continues to deliver on
6-K - ARGENX SE (0001697862) (Filer)
6-K - ARGENX SE (0001697862) (Filer)
6-K - ARGENX SE (0001697862) (Filer)
SC 13G/A - ARGENX SE (0001697862) (Subject)
SC 13G/A - ARGENX SE (0001697862) (Subject)
SC 13G/A - ARGENX SE (0001697862) (Subject)
January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f
December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. "argenx continues to deliver on
October 23, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium 32 800 50 201Franc
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up